AUS
NZ
UK
CA
USA
IND
Highlights:
- Halma acquires Lamidey Noury Medical for €50m (£42m) to enhance its portfolio of advanced medical technologies.
- Lamidey Noury, based in France, manufactures electrosurgical devices for minimally invasive surgery, with products sold in over 60 countries.
- The acquisition strengthens Halma's position in the urology and gynaecology sectors, complementing its existing healthcare offerings.
Halma plc (HLMA: LSE), a global leader in life-saving technologies, has announced the acquisition of Lamidey Noury Medical, a French company renowned for its advanced electrosurgical and energy-based medical devices. The acquisition, valued at €50 million (approximately £42 million) on a cash- and debt-free basis, marks a significant step in Halma’s strategy to expand its healthcare sector and improve patient outcomes through innovative surgical technologies.
Founded in 1947 and headquartered near Paris, Lamidey Noury Medical specializes in the development and manufacturing of electrosurgical instruments used in minimally invasive procedures. These products are predominantly employed in urology, gynaecology, and general surgery, addressing the growing demand for advanced tools that enable safer, more efficient surgeries. The company’s products are sold to healthcare providers in over 60 countries, expanding its reach in key international markets.
The deal is structured as a cash purchase, funded by Halma’s existing financial resources, and will see Lamidey Noury operate as a standalone business unit within Halma’s Healthcare Sector. The company’s current management team will remain in place, ensuring continuity and stability as Lamidey Noury continues to expand globally.
For Halma, this acquisition further strengthens its position in the healthcare market, particularly in the areas of minimally invasive surgery and surgical energy devices. Lamidey Noury’s advanced technologies align well with Halma’s existing medical offerings, which include diagnostic and biopsy devices through its subsidiaries Rovers Medical Devices and IZI Medical. By acquiring Lamidey Noury, Halma will broaden its capabilities in the urology and gynaecology markets—two sectors experiencing significant growth due to the rising incidence of diseases requiring surgical intervention.
Marc Ronchetti, Group Chief Executive of Halma, commented on the acquisition, saying, “Lamidey Noury is an exciting acquisition which will bring new minimally invasive surgical product capabilities to our Healthcare Sector. Its advanced products improve patient outcomes and the efficiency of healthcare providers in treating the increasing incidence of urological and gynaecological disease. It is adjacent to our existing presence in diagnosis and biopsy devices for these diseases, and we look forward to supporting its development as it scales globally.”
Lamidey Noury’s innovative surgical products, designed to improve surgical precision and reduce recovery times, are expected to complement Halma’s broader healthcare portfolio. With a strong track record of research and development in electrosurgery, Lamidey Noury will enhance Halma’s ability to provide integrated solutions for healthcare providers.
Guillaume Noury, President of Lamidey Noury, expressed his enthusiasm for joining the Halma family, noting that the partnership would provide significant opportunities for growth. “Joining Halma is an exciting opportunity for us. Leveraging Halma's expertise, resources, and global reach will accelerate our growth and innovation. We are confident in our ability to continue delivering high-quality surgical tools to our customers worldwide, while providing new opportunities for our employees and stakeholders.”
In 2024, Lamidey Noury reported unaudited revenue of €13.6 million (approximately £11.4 million), with an EBIT margin above Halma’s target range of 19-23%. The company’s strong financial performance underscores its potential for continued growth within Halma’s expansive network.
With this acquisition, Halma continues to build on its strategy of acquiring businesses that offer life-saving technologies and have strong growth potential. Lamidey Noury’s expertise in electrosurgical products will further cement Halma’s position as a leading provider of cutting-edge medical devices, improving the quality of care and outcomes for patients worldwide.
